(Q54579352)

English

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

author name string

Kyung Kee Baek

1

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

Jung-Hoon Kim

2

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

Ji Eun Uhm

3

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

Se Hoon Park

4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

Jeeyun Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

Joon Oh Park

6

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

Young Suk Park

7

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

Won Ki Kang

8

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

Ho Yeong Lim

9

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

publication date

24 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

80

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

3-4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

167-174

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

Annual Report of the Korea Central Cancer Registry Program 2000: Based on Registered Data from 131 Hospitals

1 reference

https://api.crossref.org/works/10.1159%2F000327591

21 January 2018

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1159%2F000327591

21 January 2018

Systemic therapy for advanced hepatocellular carcinoma: a review.

1 reference

https://api.crossref.org/works/10.1159%2F000327591

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1159%2F000327591

21 January 2018

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000327591

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000327591

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000327591

21 January 2018

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

https://api.crossref.org/works/10.1159%2F000327591

21 January 2018

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

1 reference

https://api.crossref.org/works/10.1159%2F000327591

21 January 2018

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000327591

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1159%2F000327591

21 January 2018

Novel advancements in the management of hepatocellular carcinoma in 2008.

1 reference

https://api.crossref.org/works/10.1159%2F000327591

21 January 2018

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

1 reference

https://api.crossref.org/works/10.1159%2F000327591

21 January 2018

Identifiers

10.1159/000327591

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21701230

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54579352&oldid=1980438669"